HKG:3613 Tong Ren Tang Already 8 years a Dividend Challenger. Medicine should be doing okay in a pandemic. This company has a payout ratio of 30%. Apparently the gowth of Net Profit is negative. Still a 4% dividend growth over 2020.
HKG:1681 Consun Pharm Consun Pharm (1681.HK) is making their money with medicine and medicine research. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products
HKG:1177 Sino Biopharm The Group’s business works in a fully integrated chain which spans from R&D to manufacture and sales of pharmaceutical products, covering a vast array of biopharmaceutical, chemical and modernized Chinese medicines. P?e is on the high end and that brings Dividend yield also in a not favorable position.
HKG:1099 SINOPHARM Dividend is in RMB also here. Other than that, things look nice. Not too splendid on the yield side , but consistent growth in dividend. So sit and wait till the time is right.
HKG:0867 CMS The main activities of CMS 0867.HK are pretty straight forward: the production of medicines, marketing, promotion and sale of drugs.
Blue Chip Stock CSPC Pharma HKG:1093 August 2020 the first Interim Dividend was announced. For CSPC Pharma Dividend Growth and Safety look promising, but is this a dividend stock that will keep growing? It did for the last 5 years. Well with a P/E and Price-to-book ratios like this, the price seems higher than the […]
Blue Chip Stock Sino Biopharm HKG:1177 Updated: June 14, 2022 Ex Dividend: 15-Jun Quick glance, Price-to-earnings (P/E ratio): 4.79 Price-to-Book ratio : 2.18 preferably <1 although some value investors like it till <3 Earnings per Share (EPS): 0.86 BETA: 0.71 A Beta greater than 1.0 might indicate that the stock is more volatile than the […]